未来的流感疫苗与基因重组体的应用。
Future influenza vaccines and the use of genetic recombinants.
作者信息
Kilbourne E D
出版信息
Bull World Health Organ. 1969;41(3):643-5.
Abstract
Genetic recombination of influenza viruses provides the possibility of immediate reassortment and combination of genes and gene products in a single step. Thus, genetic variants with desirable attributes for vaccine production can be produced by deliberate genetic manipulation of viruses rather than by the empirical "hit or miss" methods of the past. Recombination of a high-yield laboratory strain (A0/PR/8) with a low-yield Hong Kong virus (Aichi strain) produced a high-yield recombinant virus (X-31) of Hong Kong antigenicity suitable for vaccine production. It is proposed that a prefabricated "library" of recombinants might anticipate the mutations which may arise in the future and also that live virus vaccines of greater stability may be produced by recombination of new and old viruses.
摘要
流感病毒的基因重组提供了在一步中立即进行基因和基因产物重配和组合的可能性。因此，可以通过对病毒进行有意的基因操作来产生具有疫苗生产所需特性的遗传变体，而不是采用过去那种经验性的“碰运气”方法。高产实验室毒株（A0/PR/8）与低产香港病毒（爱知毒株）的重组产生了具有香港抗原性的适合疫苗生产的高产重组病毒（X-31）。有人提出，预制的重组体“文库”可能会预测未来可能出现的突变，而且通过新老病毒的重组可能会生产出稳定性更高的活病毒疫苗。
相似文献
1
Future influenza vaccines and the use of genetic recombinants.未来的流感疫苗与基因重组体的应用。
Bull World Health Organ. 1969;41(3):643-5.
2
Comparison of the haemagglutinin production of influenza A2 Hong Kong variant and recombinant strains.甲型流感病毒香港变异株与重组株血凝素产生情况的比较。
Bull World Health Organ. 1970;43(2):275-9.
3
Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.野生型A/悉尼/5/97流感病毒与减毒活疫苗株之间定向基因片段重配产生的表型特性。
Virology. 2007 Oct 25;367(2):275-87. doi: 10.1016/j.virol.2007.05.004. Epub 2007 Jun 28.
4
5
Recombinant influenza-virus vaccines: I. Rapid derivation and preliminary characterization of high-yielding recombinants of influenza virus.重组流感病毒疫苗：I. 流感病毒高产重组体的快速衍生及初步特性分析
Kitasato Arch Exp Med. 1976 Jun;49(1-2):1-26.
6
Laboratory and clinical evaluation of new live influenza virus vaccines. Need for minimum requirements.
Dev Biol Stand. 1977;39:155-60.
7
High-yield reassortant influenza vaccine production virus has a mutation at an HLA-A 2.1-restricted CD8+ CTL epitope on the NS1 protein.
Virology. 1999 Jun 20;259(1):135-40. doi: 10.1006/viro.1999.9719.
8
Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.一种甲型H5N2重配病毒作为针对具有大流行潜力的高致病性H5N1病毒的减毒活疫苗和灭活疫苗候选株的特性分析。
Vaccine. 2006 Nov 17;24(47-48):6859-66. doi: 10.1016/j.vaccine.2006.06.023. Epub 2006 Jun 28.
9
Conditions for production of thermosensitive attenuated influenza virus recombinants.
Acta Virol. 1978 Jul;22(4):263-9.
10
[Genetic techniques for the production of influenza vaccines (author's transl)].[生产流感疫苗的基因技术（作者译）]
Ann Sclavo. 1980 Jan-Feb;22(1):34-9.
引用本文的文献
1
Novel Minimal Absent Words Detected in Influenza A Virus.甲型流感病毒中检测到的新型最小缺失词
Viruses. 2025 Apr 30;17(5):659. doi: 10.3390/v17050659.
2
Understanding Influenza.了解流感
Methods Mol Biol. 2025;2890:1-26. doi: 10.1007/978-1-0716-4326-6_1.
3
The Altered Neonatal CD8 T Cell Immunodominance Hierarchy during Influenza Virus Infection Impacts Peptide Vaccination.流感病毒感染期间改变的新生儿 CD8 T 细胞免疫优势等级影响肽疫苗接种。
Viruses. 2024 Aug 9;16(8):1271. doi: 10.3390/v16081271.
4
Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus.针对乙型流感病毒两个谱系的交叉反应性减毒活流感疫苗候选株的研发
Vaccines (Basel). 2024 Jan 18;12(1):95. doi: 10.3390/vaccines12010095.
5
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.T 细胞刺激疫苗增强了 CD3 双特异性抗体疗法在实体肿瘤中的疗效。
Nat Commun. 2024 Jan 2;15(1):48. doi: 10.1038/s41467-023-44308-6.
6
Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens.靶向 MR1-MAIT 细胞轴可提高疫苗疗效并提供针对病毒病原体的保护。
PLoS Pathog. 2023 Jun 29;19(6):e1011485. doi: 10.1371/journal.ppat.1011485. eCollection 2023 Jun.
7
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].[卫生技术评估：一种基于价值的医疗技术评估工具。细胞培养衍生四价流感疫苗Flucelvax Tetra 2.0的重新评估]
J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec.
8
Single Particle Analysis of H3N2 Influenza Entry Differentiates the Impact of the Sialic Acids (Neu5Ac and Neu5Gc) on Virus Binding and Membrane Fusion.单颗粒分析 H3N2 流感病毒进入可区分唾液酸（Neu5Ac 和 Neu5Gc）对病毒结合和膜融合的影响。
J Virol. 2023 Mar 30;97(3):e0146322. doi: 10.1128/jvi.01463-22. Epub 2023 Feb 13.
9
Superinfection exclusion creates spatially distinct influenza virus populations.继发感染排除会导致流感病毒群体在空间上产生差异。
PLoS Biol. 2023 Feb 9;21(2):e3001941. doi: 10.1371/journal.pbio.3001941. eCollection 2023 Feb.
10
Hemagglutinin stalk-binding antibodies enhance effectiveness of neuraminidase inhibitors against influenza via Fc-dependent effector functions.血凝素茎结合抗体通过 Fc 依赖性效应功能增强神经氨酸酶抑制剂对流感的疗效。
Cell Rep Med. 2022 Aug 16;3(8):100718. doi: 10.1016/j.xcrm.2022.100718.
本文引用的文献
1
Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8.流感病毒的遗传学研究。I. 病毒形态和生长能力作为可交换的遗传特性。通过与PR8组合对早期传代亚洲株分离物进行卵内快速适应性培养。
J Exp Med. 1960 Mar 1;111(3):387-406. doi: 10.1084/jem.111.3.387.
2
Identification in a recombinant influenza virus of structural proteins derived from both parents.在重组流感病毒中鉴定出来自双亲的结构蛋白。
Virology. 1966 Nov;30(3):493-501. doi: 10.1016/0042-6822(66)90125-5.
3
Recombination of influenza A viruses of human and animal origin.人类和动物源甲型流感病毒的重组
Science. 1968 Apr 5;160(3823):74-6. doi: 10.1126/science.160.3823.74.
4
Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus.流感病毒血凝素和神经氨酸酶抗原性质的独立变异：香港-68病毒血凝素抗原的独特性
Proc Natl Acad Sci U S A. 1969 Jun;63(2):326-33. doi: 10.1073/pnas.63.2.326.
Zotero 插件